All Title Author
Keywords Abstract

Outcome of anthroposophic medication therapy in chronic disease: A 12-month prospective cohort study


Keywords: anthroposophy, chronic disease, drug therapy, outcome and process assessment (health care), prospective studies, quality of life

Full-Text   Cite this paper   Add to My Lib


tcome of anthroposophic medication therapy in chronic disease: A 12-month prospective cohort study (3530) Total Article Views Authors: Harald J Hamre, Claudia M Witt, Anja Glockmann, Renatus Ziegler, Gunver S Kienle et al Published Date January 2008 Volume 2008:2 Pages 25 - 37 DOI: Harald J Hamre1, Claudia M Witt2, Anja Glockmann1, Renatus Ziegler3, Gunver S Kienle1, Stefan N Willich2, Helmut Kiene1 1Institute for Applied Epistemology and Medical Methodology, Freiburg, Germany; 2Institute of Social Medicine, Epidemiology, and Health Economics, Charité University Medical Center, Berlin, Germany; 3Society for Cancer Research, Arlesheim, Switzerland Background: Anthroposophic medications (AMED) are prescribed in 56 countries. Objective: To study clinical outcomes in patients prescribed AMED for chronic disease. Design: Prospective cohort study. Setting: 110 medical practices in Germany. Participants: 665 consecutive outpatients aged 1–71 years, prescribed AMED for mental, respiratory, musculoskeletal, neurological, genitourinary, and other chronic diseases. Main outcomes: Disease and Symptom Scores (physicians’ and patients’ assessment, 0–10) and SF-36. Results: During the first six months, an average of 1.5 AMED per patient was used, in total 652 different AMED. Origin of AMED was mineral (8.0% of 652 AMED), botanical (39.0%), zoological (7.2%), chemically defined (13.0%), and mixed (33.0%). From baseline to six-month follow-up, all outcomes improved significantly: Disease Score improved by mean 3.15 points (95% confidence interval 2.97–3.34, p 0.001), Symptom Score by 2.43 points (2.23–2.63, p 0.001), SF-36 Physical Component Summary by 3.04 points (2.16–3.91, p 0.001), and SF-36 Mental Component Summary by 5.75 points (4.59–6.92, p 0.001). All improvements were maintained at 12-month follow-up. Improvements were similar in adult men and women, in children, and in patients not using adjunctive therapies. Conclusion: Outpatients using AMED for chronic disease had long-term reduction of disease severity and improvement of quality of life.


comments powered by Disqus